All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Cancer Care in 2024: Striving to Overcome the Challenges

August 21st 2024

Manmeet S. Ahluwalia, MD, MBA, FASCO, discusses ongoing efforts to overcome challenges in cancer care in 2024.

Repotrectinib Adds to the Treatment Armamentarium for NTRK+ Advanced Solid Tumors

August 21st 2024

Luis E. Raez, MD, FACP, FCCP, FASCO, discusses the FDA approval of repotrectinib for NTRK-positive advanced solid tumors.

Targeted Cancer Vaccines Could Shift the Paradigm for HPV+ HNSCC

August 21st 2024

Katharine A. Price, MD, discusses the use of HPV-targeted immunotherapy vaccines in patients with HPV16-positive head and neck squamous cell carcinoma.

Future Perioperative Trial Designs in NSCLC Need Adjustments Per FDA ODAC Consensus

August 20th 2024

John V. Heymach, MD, PhD, and Marina Chiara Garassino, MD, discuss data with perioperative durvalumab in resectable NSCLC in light of the ODAC decision.

The US Oncology Network Expands its Tennessee Service Area as Tennessee Cancer Specialists Joins The Network

August 20th 2024

Tennessee Cancer Specialists, the third largest oncology practice in the state, strengthens its ability to deliver cutting-edge advanced care by joining The Network.

FDA Grants BTD to GSK5764227 for Extensive-Stage Small Cell Lung Cancer

August 20th 2024

GSK5764227 has received breakthrough therapy designation from the FDA for use in select patients with extensive-stage small cell lung cancer.

Sacituzumab Tirumotecan NDA for EGFR+ NSCLC Under Review in China

August 20th 2024

An NDA seeking approval of sacituzumab tirumotecan for select patients with EGFR+ non–small cell lung cancer has been accepted by the NMPA's CDE.

Enfortumab Vedotin Approved in China for Locally Advanced/Metastatic Urothelial Cancer

August 20th 2024

China’s National Medical Products Administration has approved enfortumab vedotin for adult patients with locally advanced or metastatic urothelial cancer.

The Importance of Oral Medicine in Cancer: Evaluation and Treatment

August 20th 2024

Alessandro Villa, DDS, PhD, MPH, discusses the importance of oral medicine in cancer treatment.

Awareness Efforts Needed to Address Genetic Testing Disparities Among Male BRCA1/2 Carriers

August 20th 2024

Males harboring BRCA1/2 pathologic variants have a higher risk of developing select cancers but are less likely to undergo genetic testing.

Epcoritamab Wins EU Approval for Relapsed/Refractory Follicular Lymphoma

August 20th 2024

The European Commission has granted conditional marketing authorization to epcoritamab for patients with relapsed or refractory follicular lymphoma.

FDA Approves First-Line Amivantamab Plus Lazertinib for EGFR+ Advanced NSCLC

August 20th 2024

The FDA has approved first-line amivantamab plus lazertinib for locally advanced or metastatic EGFR-mutated non–small cell lung cancer.

Oncology Community Mourns the Loss of Dr Jeffrey S. Weber, 2016 Giant of Cancer Care® Winner

August 19th 2024

Jeffrey S. Weber, MD, PhD, inductee of the 2016 Giants of Cancer Care award in Melanoma, has died.

Sacituzumab Govitecan Displays Activity in Advanced/Metastatic Endometrial Cancer

August 19th 2024

Treatment with sacituzumab govitecan led to antitumor activity in endometrial cancer and TROP-2 expression did not appear to affect response to the agent.

Sanjay S. Reddy Receives Faculty Citizenship Award From Fox Chase Cancer Center

August 19th 2024

Sanjay S. Reddy, MD, FACS, OF Fox Chase Cancer Center, recently received the center’s 2024 Medical Staff Executive Committee Faculty Citizenship Award.

FDA Awards Orphan Drug Designation to PT217 for Neuroendocrine Carcinoma

August 19th 2024

The FDA has granted orphan drug designation to PT217 for the treatment of patients with neuroendocrine carcinoma.

FDA Lifts Partial Clinical Hold on Phase 1 Trial of YL202 in Advanced NSCLC and Breast Cancer

August 19th 2024

The FDA has lifted a partial clinical hold on the phase 1 trial evaluating YL202 in advanced breast cancer and EGFR-mutated non–small cell lung cancer.

EMA Accepts Marketing Application for T-DXd in HER2-Low and -Ultralow Metastatic Breast Cancer

August 19th 2024

The EMA has validated a type II variation application for trastuzumab deruxtecan for select patients with HER2-low or -ultralow metastatic breast cancer.

EMA Validates Application for Liso-Cel in Relapsed/Refractory Follicular Lymphoma

August 19th 2024

The EMA has expanded the indication for lisocabtagene maraleucel to include the treatment of patients with relapsed or refractory follicular lymphoma.

Tumor-Killing Technology in Head and Neck Cancer

August 19th 2024

Noah Kalman, MD, MBA, details new technology for treating head and neck cancer, and ongoing trials examining therapies at Miami Cancer Institute.